Cancer clinical trials help answer important questions about medical care in an effort to develop new and improved ways to treat all patients with cancer and those who will develop cancer in the future.
Find current clinical trials offered by Duke Cancer Institute:
The Hematologic Malignancy Program is closely associated with the Duke Cancer Institute, consistently rated among the nation’s top cancer programs by U.S.News & World Report.
Patients benefit directly from Duke’s leadership in cancer research, allowing us to offer tomorrow’s innovations today in the field of cell signaling, stem cell therapies, cellular targeting, tumor immunology, and drug development.
Recent advances from the Duke Hematologic Malignancies Research Program include: